The controlled, randomized trial, which will enroll 60 patients with coronary in-stent restenosis (ISR), is designed to compare the drug-coated AngioSculpt with the existing drug uncoated version.
The drug-coated AngioSculpt’s nitinol elements provide precise and predictable luminal enlargement of various kinds of lesion types and through their anti-slippage properties avoids geographic miss.
AngioScore co-Founder and CMO Gary Gershony said extensive pre-clinical studies have showed the safety of a drug-coated AngioSculpt and its ability to have a profound effect on preventing restenosis.
